Your session is about to expire
← Back to Search
Florbetapir PET/MR scan for Amyloidosis
Study Summary
This trial will test how well PET/MR works in diagnosing amyloidosis in patients with peripheral nerve damage.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You are between 18 and 100 years old.You have metal devices in your body that are not safe for MRI scans, like pacemakers or stents.You are afraid of being in small, enclosed spaces.Your body mass index (BMI) is higher than 38.You have a confirmed condition called peripheral nerve amyloidosis or other confirmed causes of peripheral neuropathy.
- Group 1: Peripheral nerve amyloidosis
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is this research endeavor accepting those over the age of forty-five as participants?
"Potential participants must fall in the 18 to 100 years old bracket for this medical trial. There are also 2 trials specifically targeting minors and 97 studies that cater to seniors aged 65 or above."
Are there any participant slots available in this clinical trial?
"Clinicaltrials.gov shows that this trail, which was initially posted on March 13th 2017 and modified most recently on January 14th 2022, is no longer actively recruiting patients. However, 97 other trials are still accepting new candidates at the present moment."
Who is eligible to partake in this medical trial?
"This research project requires 10 people aged between 18 and 100 who have been diagnosed with amyloidosis. Candidates must also match the following criteria: Adults of ages ranging from 18 to 100, histologically-verified peripheral nerve amyloidosis or pathogenetically-confirmed non-amyloid sources of peripheral neuropathy."
What purpose does this medical experiment seek to fulfill?
"This study seeks to measure uptake of 18-F Florbetapir in nerve tissue over a timeframe ranging from 50 minutes to 120 minutes post injection. Secondary objectives include gauging the T1 and T2 characteristics (Hypointense, isointense or hyperintense relative to skeletal muscle), pattern of contrast enhancement (Solid, heterogeneous or peripheral enhancement) and morphological changes (Presence or absence of neural enlargement). All are categorical variables without an associated quantitative scale."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger